Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397081 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1902097 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21466110 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL9383870 | 0.91 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1440010 | 0.91 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1439328 | 0.91 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL26789869 | 0.91 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL19179977 | 0.90 | UCHL1 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL13662049 | 0.89 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL16772779 | 0.88 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349988-B | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | 卡鲁斯治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-10442815-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| WO-2017029521-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8039675-B2 | Catalysts | JOHNSON MATTHEY PLC (GB) | 2011-10-18 | — | — | US | disclosed |
| US-20100197976-A1 | CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2010-08-05 | — | — | US | disclosed |
| EP-1849792-B1 | Biphosphine ruthenium complexes with chiral diamine ligands as catalysts | JOHNSON MATTHEY PLC (GB) | 2008-12-10 | — | — | EP | disclosed |
| EP-1849792-A1 | Biphosphine ruthenium complexes with chiral diamine ligands as catalysts | Johnson Matthey PLC (GB) | 2007-10-31 | — | — | EP | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1651657-B1 | BIPHOSPHINE RUTHENIUM COMPLEXES WITH CHIRAL DIAMINE LIGANDS AS CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2007-08-22 | — | — | EP | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066850-A1 | Catalysts | JOHNSON MATTHEY PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| EP-1651657-A2 | BIPHOSPHINE RUTHENIUM COMPLEXES WITH CHIRAL DIAMINE LIGANDS AS CATALYSTS | Johnson Matthey PLC (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005007662-A2 | BIPHOSPHINE RUTHENIUM COMPLEXES WITH CHIRAL DIAMINE LIGANDE AS CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066850-A1 | Catalysts | HRH3, PRMT1, HRH4 | NR1H2 272/4885CHRM2 131/4885CHRM1 60/4885 |
| US-20100197976-A1 | CATALYSTS | HRH3, HRH2, PRMT8 | NR1H2 277/4885CHRM2 167/4885CHRM1 91/4885 |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | NR1H2 3695/4885CHRM2 4728/4885CHRM1 4621/4885 |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTB4R2 | NR1H2 439/4885CHRM2 954/4885CHRM1 484/4885 |
| US-10442815-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | PIK3CD, PIK3CA, PIK3C2B | NR1H2 2881/4885CHRM2 4684/4885CHRM1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.